Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

6-Hydroxydopamine impairs mitochondrial function in the rat model of Parkinson's disease: respirometric, histological, and behavioral analyses.

Kupsch A, Schmidt W, Gizatullina Z, Debska-Vielhaber G, Voges J, Striggow F, Panther P, Schwegler H, Heinze HJ, Vielhaber S, Gellerich FN.

J Neural Transm (Vienna). 2014 Oct;121(10):1245-57. doi: 10.1007/s00702-014-1185-3. Epub 2014 Mar 14.

PMID:
24627045
2.

Graded 6-OHDA-induced dopamine depletion in the nigrostriatal pathway evokes progressive pathological neuronal activities in the subthalamic nucleus of a hemi-parkinsonian mouse.

Park SE, Song KI, Kim H, Chung S, Youn I.

Behav Brain Res. 2018 May 15;344:42-47. doi: 10.1016/j.bbr.2018.02.014. Epub 2018 Feb 13.

PMID:
29452192
3.

Developing a preclinical model of Parkinson's disease: a study of behaviour in rats with graded 6-OHDA lesions.

Truong L, Allbutt H, Kassiou M, Henderson JM.

Behav Brain Res. 2006 Apr 25;169(1):1-9. Epub 2006 Jan 4.

PMID:
16413939
4.

The 6-OHDA mouse model of Parkinson's disease - Terminal striatal lesions provide a superior measure of neuronal loss and replacement than median forebrain bundle lesions.

Bagga V, Dunnett SB, Fricker RA.

Behav Brain Res. 2015 Jul 15;288:107-17. doi: 10.1016/j.bbr.2015.03.058. Epub 2015 Apr 2.

PMID:
25841616
5.

A partial lesion model of Parkinson's disease in mice--characterization of a 6-OHDA-induced medial forebrain bundle lesion.

Boix J, Padel T, Paul G.

Behav Brain Res. 2015 May 1;284:196-206. doi: 10.1016/j.bbr.2015.01.053. Epub 2015 Feb 16.

6.

Intranasally-administered deferoxamine mitigates toxicity of 6-OHDA in a rat model of Parkinson׳s disease.

Fine JM, Forsberg AC, Renner DB, Faltesek KA, Mohan KG, Wong JC, Arneson LC, Crow JM, Frey WH 2nd, Hanson LR.

Brain Res. 2014 Jul 29;1574:96-104. doi: 10.1016/j.brainres.2014.05.048. Epub 2014 Jun 10.

PMID:
24928620
7.

A time-course study of behavioral and electrophysiological characteristics in a mouse model of different stages of Parkinson's disease using 6-hydroxydopamine.

Park SE, Song KI, Suh JK, Hwang D, Youn I.

Behav Brain Res. 2015 May 1;284:153-7. doi: 10.1016/j.bbr.2015.02.019. Epub 2015 Feb 16.

PMID:
25698596
8.

Comparative study of the neurotrophic effects elicited by VEGF-B and GDNF in preclinical in vivo models of Parkinson's disease.

Yue X, Hariri DJ, Caballero B, Zhang S, Bartlett MJ, Kaut O, Mount DW, Wüllner U, Sherman SJ, Falk T.

Neuroscience. 2014 Jan 31;258:385-400. doi: 10.1016/j.neuroscience.2013.11.038. Epub 2013 Nov 27.

9.

Allogeneic/xenogeneic transplantation of peptide-labeled mitochondria in Parkinson's disease: restoration of mitochondria functions and attenuation of 6-hydroxydopamine-induced neurotoxicity.

Chang JC, Wu SL, Liu KH, Chen YH, Chuang CS, Cheng FC, Su HL, Wei YH, Kuo SJ, Liu CS.

Transl Res. 2016 Apr;170:40-56.e3. doi: 10.1016/j.trsl.2015.12.003. Epub 2015 Dec 15.

PMID:
26730494
10.

LPA signaling is required for dopaminergic neuron development and is reduced through low expression of the LPA1 receptor in a 6-OHDA lesion model of Parkinson's disease.

Yang XY, Zhao EY, Zhuang WX, Sun FX, Han HL, Han HR, Lin ZJ, Pan ZF, Qu MH, Zeng XW, Ding Y.

Neurol Sci. 2015 Nov;36(11):2027-33. doi: 10.1007/s10072-015-2295-x. Epub 2015 Jul 14.

PMID:
26169757
11.

Sensorimotor assessment of the unilateral 6-hydroxydopamine mouse model of Parkinson's disease.

Glajch KE, Fleming SM, Surmeier DJ, Osten P.

Behav Brain Res. 2012 May 1;230(2):309-16. doi: 10.1016/j.bbr.2011.12.007. Epub 2011 Dec 9.

12.
13.

Differential effects of intrastriatal 6-hydroxydopamine on cell number and morphology in midbrain dopaminergic subregions of the rat.

Healy-Stoffel M, Omar Ahmad S, Stanford JA, Levant B.

Brain Res. 2014 Jul 29;1574:113-9. doi: 10.1016/j.brainres.2014.05.045. Epub 2014 Jun 9.

14.

Early post-treatment with 9-cis retinoic acid reduces neurodegeneration of dopaminergic neurons in a rat model of Parkinson's disease.

Yin LH, Shen H, Diaz-Ruiz O, Bäckman CM, Bae E, Yu SJ, Wang Y.

BMC Neurosci. 2012 Oct 6;13:120. doi: 10.1186/1471-2202-13-120.

15.

Nicotine-Induced Neuroprotection in Rotenone In Vivo and In Vitro Models of Parkinson's Disease: Evidences for the Involvement of the Labile Iron Pool Level as the Underlying Mechanism.

Mouhape C, Costa G, Ferreira M, Abin-Carriquiry JA, Dajas F, Prunell G.

Neurotox Res. 2019 Jan;35(1):71-82. doi: 10.1007/s12640-018-9931-1. Epub 2018 Jul 13.

PMID:
30006684
16.

Intracranial application of near-infrared light in a hemi-parkinsonian rat model: the impact on behavior and cell survival.

Reinhart F, Massri NE, Chabrol C, Cretallaz C, Johnstone DM, Torres N, Darlot F, Costecalde T, Stone J, Mitrofanis J, Benabid AL, Moro C.

J Neurosurg. 2016 Jun;124(6):1829-41. doi: 10.3171/2015.5.JNS15735. Epub 2015 Nov 27.

PMID:
26613166
17.

Stress reduces the neuroprotective effect of exercise in a rat model for Parkinson's disease.

Howells FM, Russell VA, Mabandla MV, Kellaway LA.

Behav Brain Res. 2005 Dec 7;165(2):210-20. Epub 2005 Sep 12.

PMID:
16159673
18.

DJ-1 protein protects dopaminergic neurons against 6-OHDA/MG-132-induced neurotoxicity in rats.

Sun SY, An CN, Pu XP.

Brain Res Bull. 2012 Sep 1;88(6):609-16. doi: 10.1016/j.brainresbull.2012.05.013. Epub 2012 Jun 1.

PMID:
22664331
19.

High frequency stimulation of subthalamic nucleus results in behavioral recovery by increasing striatal dopamine release in 6-hydroxydopamine lesioned rat.

He Z, Jiang Y, Xu H, Jiang H, Jia W, Sun P, Xie J.

Behav Brain Res. 2014 Apr 15;263:108-14. doi: 10.1016/j.bbr.2014.01.014. Epub 2014 Jan 23.

PMID:
24462728
20.

Characterization of gray matter atrophy following 6-hydroxydopamine lesion of the nigrostriatal system.

Westphal R, Sumiyoshi A, Simmons C, Mesquita M, Wood TC, Williams SC, Vernon AC, Cash D.

Neuroscience. 2016 Oct 15;334:166-179. doi: 10.1016/j.neuroscience.2016.07.046. Epub 2016 Aug 6.

PMID:
27506141

Supplemental Content

Support Center